{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001880438","name":"AN2 Therapeutics, Inc.","summary":"AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule therapeutics derived from its boron chemistry platform. Its pipeline includes epetraborole (targeting polycythemia vera and M. abscessus lung disease), AN2-502998 (targeting Chagas disease), and preclinical oncology programs targeting PI3K and ENPP1. The company also pursues global health programs in melioidosis and tuberculosis, funded primarily through non-dilutive grants.","people":[],"products":[{"name":"Epetraborole","type":"platform","description":"Oral small-molecule boron-based compound in Phase 2 development for polycythemia vera and M. abscessus lung disease."},{"name":"AN2-502998","type":"platform","description":"Oral boron-based compound in Phase 1 first-in-human trial for chronic Chagas disease; only compound shown curative activity in NHP models."},{"name":"PI3K Inhibitor Program","type":"platform","description":"Preclinical pan-mutant PI3K inhibitor targeting kinase and helical domain mutations in solid tumors without hyperglycemia in models."},{"name":"ENPP1 Inhibitor Program","type":"platform","description":"Preclinical boron-based ENPP1 inhibitor designed to preserve cGAMP signaling and enhance antitumor immunity in solid tumors."}],"partnerships":[{"partner_name":"Anacor Pharmaceuticals, Inc.","partnership_type":"licensing","description":"Worldwide exclusive license for epetraborole and related compounds for all human diseases, executed November 2019.","start_date":null},{"partner_name":"Oregon Health and Sciences University (OHSU)","partnership_type":"development","description":"Collaboration on Phase 2 investigator-initiated study evaluating epetraborole for M. abscessus complex lung disease.","start_date":null},{"partner_name":"Gates Foundation","partnership_type":"development","description":"Partnership supporting global health tuberculosis program using boron chemistry platform.","start_date":null},{"partner_name":"GSK","partnership_type":"licensing","description":"Non-exclusive license under chiral synthesis IP for manufacturing epetraborole and related compounds; also tuberculosis partnership.","start_date":null}],"affiliations":[],"origin":{"leaf":"f7f16ed174d09a74193cc3756e43d1ce76787b87c6d83ce8f63667dfd3069868","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"a8a0f0eb4689b3554da61e9a4d7109b930d0334955530c87e3e93cbb4e3d4e3a","parent":"717ead438616dc80089dc7d15e36eeaefde27415285b859755ca82a020ff3785","source":"0001193125-26-110693","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":85,"hourly_limit":500,"remaining":415,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}